Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tearing Down The Goalposts (Part 3): “Was It Worth It”?

Executive Summary

When US FDA adopted new outcomes standards for novel diabetes drugs in 2008, there were dire warnings that it would kill product development for the disease. When an advisory committee revisited the issue in 2018, however, there was almost unanimous agreement that the guidelines have been positive. Almost. 
Advertisement

Related Content

Diabetes Drugs: Longer, Broader Phase II/III Trials Could Replace CV Outcomes Trials, US Panel Says
Diabetes Outcomes Trial Requirement Looks 'Increasingly Wise' – FDA’s Temple

Topics

Advertisement
UsernamePublicRestriction

Register

PS124182

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel